poster

Safety, Tolerability, and Efficacy of Zuranolone Repeat Treatment Courses in Adult Patients With Major Depressive Disorder–An Analysis of the Open-Label, Phase 3 SHORELINE Study

Abstract: Introduction Rapid response and episodic treatment potential are important in the treatment of major depressive disorder (MDD). Zuranolone is a neuroactive steroid and positive ...

01/19/2023

Full Range of Clinical Improvement in Depression Symptoms With Adjunctive Cariprazine Treatment in Patients With Major Depressive Disorder: Results From a Randomized Phase 3 Clinical Trial

Abstract: Background: Clinical trial results often report mean changes, though individual responses may be more valuable in clinical practice. This analysis explored the ability of adjunc...

01/19/2023

Viloxazine Extended-Release Capsules (Qelbree®) for Adults with Attention-Deficit/Hyperactivity Disorder: Evaluating the Potential Impact of Caffeine Exposure on Safety Profile

Abstract: Viloxazine ER (viloxazine extended-release capsules, Qelbree®) is a novel, nonstimulant, FDA-approved treatment for adults and children (≥6 yrs) with ADHD. Viloxazine ER inhibit...

01/19/2023

Depressive Symptom Severity in Patients with Major Depressive Disorder (MDD) at Study Exit in the One-Year SHORELINE Study of Episodic Treatment with Zuranolone

Abstract: Introduction Zuranolone is an investigational neuroactive steroid and positive allosteric modulator of synaptic and extrasynaptic GABAA receptors in clinical development as an o...

01/19/2023

Safety and Efficacy of Zuranolone in Young Adults With Major Depressive Disorder: A Subgroup Analysis of the Open-Label, Long-Term, Phase 3 SHORELINE Study

Abstract: Introduction There is a greater prevalence of major depressive disorder (MDD) in young adults compared with older adults. Zuranolone is a neuroactive steroid and positive allost...

01/19/2023

Cariprazine for the Adjunctive Treatment of Major Depressive Disorder: Results of a Randomized Phase 3 Placebo-Controlled Study (Study 301)

Abstract: Background: Patients with MDD often do not respond to antidepressant (ADT) monotherapy. Cariprazine (CAR) is under investigation as adjunctive therapy for patients with MDD. M...

01/19/2023

Safety and Tolerability of Cariprazine for the Adjunctive Treatment of Major Depressive Disorder: A Pooled Analysis of Phase 2B and 3 Clinical Trials

Abstract: Background: Safety of cariprazine in patients with major depressive disorder (MDD) with inadequate response to antidepressants was evaluated. Methods: Safety, tolerability, and ...

01/19/2023

Efficacy of Cariprazine as Adjunctive Treatment of Major Depressive Disorder in Patients with Anxiety at Baseline: A Post Hoc Analysis of a Randomized Controlled Trial

Abstract: Background: The efficacy of adjunctive cariprazine treatment on depressive symptoms was evaluated in patients with major depressive disorder (MDD) and inadequate response to ant...

01/19/2023

Pimavanserin treatment of hallucinations and delusions in patients with Parkinson’s disease dementia: post hoc analysis of the HARMONY trial

Abstract: Introduction: Pimavanserin 34 mg is approved in the US to treat hallucinations and delusions associated with Parkinson’s Disease psychosis (PDP). The efficacy and safety of pima...

01/19/2023

Understanding the Use of Long-Acting Injectable Antipsychotic Agents in Schizophrenia: A 2022 Survey of US Psychiatrists, Nurse Practitioners, and Physician Associates

Abstract: Background: Treatment with long-acting injectable antipsychotic agents (LAIs) has been shown to improve outcomes in schizophrenia; however, many healthcare providers continue to...

01/19/2023

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products